Loading...

Ocular Therapeutix

DB:0OT
Snowflake Description

High growth potential with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
0OT
DB
$156M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The last earnings update was 43 days ago. More info.


Add to Portfolio Compare Print
  • Ocular Therapeutix has significant price volatility in the past 3 months.
0OT Share Price and Events
7 Day Returns
-7.9%
DB:0OT
-1.2%
DE Pharmaceuticals
2.4%
DE Market
1 Year Returns
-38.5%
DB:0OT
-21.8%
DE Pharmaceuticals
-6.2%
DE Market
0OT Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Ocular Therapeutix (0OT) -7.9% -10.8% -8.7% -38.5% -72.8% -
DE Pharmaceuticals -1.2% -8.1% -2.2% -21.8% -25.2% 7.6%
DE Market 2.4% 3% 7.4% -6.2% 9.6% 14.1%
1 Year Return vs Industry and Market
  • 0OT underperformed the Pharmaceuticals industry which returned -21.8% over the past year.
  • 0OT underperformed the Market in Germany which returned -6.2% over the past year.
Price Volatility
0OT
Industry
5yr Volatility vs Market

Value

 Is Ocular Therapeutix undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Ocular Therapeutix to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Ocular Therapeutix.

DB:0OT Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 5 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.5%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:0OT
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.73
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.729 (1 + (1- 21%) (15.9%))
0.879
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.88
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (0.879 * 5.96%)
5.47%

Discounted Cash Flow Calculation for DB:0OT using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Ocular Therapeutix is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:0OT DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 5.47%)
2019 -67.00 Analyst x1 -63.53
2020 -39.90 Analyst x2 -35.87
2021 -8.55 Analyst x2 -7.29
2022 32.80 Analyst x2 26.51
2023 76.50 Analyst x2 58.62
2024 119.40 Est @ 56.08% 86.74
2025 166.35 Est @ 39.32% 114.59
2026 212.26 Est @ 27.6% 138.63
2027 253.41 Est @ 19.39% 156.92
2028 287.97 Est @ 13.64% 169.07
Present value of next 10 years cash flows $644.39
DB:0OT DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $287.97 × (1 + 0.23%) ÷ (5.47% – 0.23%)
$5,506.22
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $5,506.22 ÷ (1 + 5.47%)10
$3,232.75
DB:0OT Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $644.39 + $3,232.75
$3,877.13
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $3,877.13 / 42.84
$90.51
DB:0OT Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:0OT represents 0.87006x of NasdaqGM:OCUL
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.87006x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 90.51 x 0.87006
€78.75
Value per share (EUR) From above. €78.75
Current discount Discount to share price of €3.17
= -1 x (€3.17 - €78.75) / €78.75
96%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Ocular Therapeutix is available for.
Intrinsic value
>50%
Share price is €3.17 vs Future cash flow value of €78.75
Current Discount Checks
For Ocular Therapeutix to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Ocular Therapeutix's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Ocular Therapeutix's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Ocular Therapeutix's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Ocular Therapeutix's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:0OT PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-1.57
NasdaqGM:OCUL Share Price ** NasdaqGM (2019-04-18) in USD $3.64
Germany Pharmaceuticals Industry PE Ratio Median Figure of 6 Publicly-Listed Pharmaceuticals Companies 26.82x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.67x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Ocular Therapeutix.

DB:0OT PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:OCUL Share Price ÷ EPS (both in USD)

= 3.64 ÷ -1.57

-2.31x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Ocular Therapeutix is loss making, we can't compare its value to the DE Pharmaceuticals industry average.
  • Ocular Therapeutix is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Ocular Therapeutix's expected growth come at a high price?
Raw Data
DB:0OT PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.31x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
56.3%per year
Europe Pharmaceuticals Industry PEG Ratio Median Figure of 35 Publicly-Listed Pharmaceuticals Companies 1.77x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Ocular Therapeutix, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Ocular Therapeutix's assets?
Raw Data
DB:0OT PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.86
NasdaqGM:OCUL Share Price * NasdaqGM (2019-04-18) in USD $3.64
Germany Pharmaceuticals Industry PB Ratio Median Figure of 9 Publicly-Listed Pharmaceuticals Companies 2.39x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.85x
DB:0OT PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:OCUL Share Price ÷ Book Value per Share (both in USD)

= 3.64 ÷ 0.86

4.21x

* Primary Listing of Ocular Therapeutix.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Ocular Therapeutix is overvalued based on assets compared to the DE Pharmaceuticals industry average.
X
Value checks
We assess Ocular Therapeutix's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Ocular Therapeutix has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Ocular Therapeutix expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
56.3%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Ocular Therapeutix expected to grow at an attractive rate?
  • Ocular Therapeutix's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Ocular Therapeutix's earnings growth is expected to exceed the Germany market average.
  • Ocular Therapeutix's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:0OT Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:0OT Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 56.3%
DB:0OT Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 44.6%
Germany Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 19.5%
Germany Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 4.8%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.5%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:0OT Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:0OT Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 174 -27 117 3
2022-12-31 125 -57 27 3
2021-12-31 88 -51 -32 3
2020-12-31 58 -52 -46 4
2019-12-31 12 -52 -67 5
DB:0OT Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 2 -49 -60
2018-09-30 2 -46 -56
2018-06-30 2 -49 -56
2018-03-31 2 -48 -61
2017-12-31 2 -50 -63
2017-09-30 2 -48 -63
2017-06-30 2 -41 -57
2017-03-31 2 -39 -50
2016-12-31 2 -34 -45
2016-09-30 2 -35 -43
2016-06-30 2 -37 -44
2016-03-31 2 -36 -43

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Ocular Therapeutix's earnings are expected to grow significantly at over 20% yearly.
  • Ocular Therapeutix's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:0OT Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Ocular Therapeutix Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:0OT Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 1.25 1.45 1.05 2.00
2022-12-31 0.57 0.90 0.24 2.00
2021-12-31 -0.50 -0.44 -0.55 2.00
2020-12-31 -0.84 -0.69 -1.14 3.00
2019-12-31 -1.47 -1.04 -1.82 5.00
DB:0OT Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -1.57
2018-09-30 -1.58
2018-06-30 -1.72
2018-03-31 -2.00
2017-12-31 -2.20
2017-09-30 -2.28
2017-06-30 -2.15
2017-03-31 -1.95
2016-12-31 -1.80
2016-09-30 -1.72
2016-06-30 -1.80
2016-03-31 -1.79

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Ocular Therapeutix will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Ocular Therapeutix's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Ocular Therapeutix has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Ocular Therapeutix performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Ocular Therapeutix's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Ocular Therapeutix does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Ocular Therapeutix's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Ocular Therapeutix's 1-year growth to the DE Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Ocular Therapeutix's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Ocular Therapeutix Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:0OT Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 1.99 -59.98 23.73
2018-09-30 1.97 -55.68 19.68
2018-06-30 2.00 -56.24 21.64
2018-03-31 1.79 -61.13 26.88
2017-12-31 1.92 -63.39 30.69
2017-09-30 1.95 -63.11 32.86
2017-06-30 1.90 -57.14 29.30
2017-03-31 1.90 -49.89 23.21
2016-12-31 1.89 -44.70 17.71
2016-09-30 1.81 -42.52 15.91
2016-06-30 1.76 -44.45 15.24
2016-03-31 1.78 -43.01 14.05
2015-12-31 1.75 -39.75 13.02
2015-09-30 1.82 -37.07 12.16
2015-06-30 1.53 -32.84 11.31
2015-03-31 1.17 -29.22 9.77
2014-12-31 0.77 -28.66 8.90
2014-09-30 0.27 -24.22 6.60 -7.68
2014-06-30 0.12 -20.45 4.84 -4.89
2014-03-31 0.03 -17.15 3.70 -2.49
2013-12-31 -13.34 2.39
2012-12-31 0.01 -14.13 2.13

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Ocular Therapeutix has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Ocular Therapeutix has efficiently used its assets last year compared to the DE Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Ocular Therapeutix improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Ocular Therapeutix's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Ocular Therapeutix has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Ocular Therapeutix's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Ocular Therapeutix's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Ocular Therapeutix is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Ocular Therapeutix's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Ocular Therapeutix's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Ocular Therapeutix Company Filings, last reported 3 months ago.

DB:0OT Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 35.88 24.79 54.06
2018-09-30 45.52 14.17 56.86
2018-06-30 45.73 15.63 56.83
2018-03-31 49.18 17.09 62.91
2017-12-31 26.15 18.02 41.54
2017-09-30 35.92 17.92 51.17
2017-06-30 48.03 17.82 66.05
2017-03-31 63.91 17.72 80.38
2016-12-31 52.01 15.64 68.15
2016-09-30 62.29 15.55 75.75
2016-06-30 70.45 15.46 83.89
2016-03-31 80.17 15.37 95.46
2015-12-31 89.59 15.27 105.06
2015-09-30 98.81 15.13 113.64
2015-06-30 109.11 15.04 123.72
2015-03-31 52.07 14.95 67.42
2014-12-31 58.70 14.87 74.83
2014-09-30 65.60 14.78 80.89
2014-06-30 5.77 14.68 19.94
2014-03-31 11.15 2.00 12.75
2013-12-31 15.13 2.46 17.51
2012-12-31 19.48 4.07 23.85
  • Ocular Therapeutix's level of debt (69.1%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (16.3% vs 69.1% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Ocular Therapeutix has sufficient cash runway for 1.1 years based on current free cash flow.
  • Ocular Therapeutix has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 15.2% each year.
X
Financial health checks
We assess Ocular Therapeutix's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Ocular Therapeutix has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Ocular Therapeutix's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Ocular Therapeutix dividends.
If you bought €2,000 of Ocular Therapeutix shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Ocular Therapeutix's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Ocular Therapeutix's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:0OT Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Germany Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 3%
Germany Market Average Dividend Yield Market Cap Weighted Average of 325 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:0OT Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Ocular Therapeutix has not reported any payouts.
  • Unable to verify if Ocular Therapeutix's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Ocular Therapeutix's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Ocular Therapeutix has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Ocular Therapeutix's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Ocular Therapeutix afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Ocular Therapeutix has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Ocular Therapeutix's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Antony Mattessich
COMPENSATION $6,181,799
AGE 51
TENURE AS CEO 1.8 years
CEO Bio

Mr. Antony Mattessich has been the Chief Executive Officer and President of Ocular Therapeutix, Inc. since July 26, 2017. Mr. Mattessich serves as Managing Director of Mundipharma International Limited. He served as Regional Director of Europe Operations at Mundipharma International Limited. He has wealth of experience to Ocular Therapeutix, having held leadership roles for a number of global pharmaceutical companies across the US, Europe and Asia, including Novartis, Bristol Meyers Squibb and Merck & Co. Over the course of his career, Mr. Mattessich has developed expertise across multiple disciplines, including general management, global marketing, new product planning, R&D and business development. Mr. Mattessich was the Managing Director of one of the world’s largest privately-owned pharmaceutical companies, Mundipharma. He has been a Director of Ocular Therapeutix, Inc. since June 20, 2017. He holds a Master’s Degree in International Affairs from Colombia University and a Bachelor of Arts from University of California, Berkeley.

CEO Compensation
  • Insufficient data for Antony to compare compensation growth.
  • Antony's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Ocular Therapeutix management team in years:

1.4
Average Tenure
51
Average Age
  • The average tenure for the Ocular Therapeutix management team is less than 2 years, this suggests a new team.
Management Team

Antony Mattessich

TITLE
President
COMPENSATION
$6M
AGE
51
TENURE
1.8 yrs

Donald Notman

TITLE
Chief Financial Officer
COMPENSATION
$982K
TENURE
1.6 yrs

Michael Goldstein

TITLE
Chief Medical Officer
COMPENSATION
$1M
AGE
51
TENURE
1.6 yrs

Kevin Hanley

TITLE
Senior Vice President of Technical Operations
AGE
56
TENURE
1.3 yrs

Peter Jarrett

TITLE
Chief Scientific Officer
AGE
61

Jon Sparks

TITLE
General Counsel & Chief Intellectual Property Counsel
TENURE
1.3 yrs

William Ransone

TITLE
Vice President of Global Sales & Marketing

Pauline Ryan

TITLE
Head of Business & Corporate Development
AGE
51
TENURE
1.4 yrs

Nicole Carta

TITLE
Director of Human Resources
TENURE
1.4 yrs

Scott Corning

TITLE
Senior Vice President of Commercial
TENURE
1.3 yrs
Board of Directors Tenure

Average tenure and age of the Ocular Therapeutix board of directors in years:

4.8
Average Tenure
57
Average Age
  • The tenure for the Ocular Therapeutix board of directors is about average.
Board of Directors

Amar Sawhney

TITLE
Founder & Chairman
COMPENSATION
$2M
AGE
51
TENURE
4.8 yrs

Antony Mattessich

TITLE
President
COMPENSATION
$6M
AGE
51
TENURE
1.8 yrs

Charles Warden

TITLE
Lead Independent Director
COMPENSATION
$187K
AGE
49
TENURE
4.8 yrs

Bruce Peacock

TITLE
Director
COMPENSATION
$174K
AGE
67
TENURE
4.8 yrs

Jim O'Shea

TITLE
Director
COMPENSATION
$162K
AGE
68
TENURE
3.4 yrs

Richard Lindstrom

TITLE
Director
COMPENSATION
$163K
AGE
70
TENURE
6.4 yrs

Jassi Chadha

TITLE
Director
COMPENSATION
$150K
AGE
50
TENURE
6.3 yrs

Jeff Heier

TITLE
Director
COMPENSATION
$155K
AGE
57
TENURE
3.6 yrs

Leslie Williams

TITLE
Director
AGE
58
TENURE
0.1 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Ocular Therapeutix insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
18. Mar 19 Buy Michael Goldstein Individual 15. Mar 19 15. Mar 19 10,000 €3.67 €36,653
18. Mar 19 Buy Jeffrey Heier Individual 15. Mar 19 15. Mar 19 24,000 €3.67 €87,967
14. Mar 19 Buy Richard Lindstrom Individual 13. Mar 19 13. Mar 19 56,441 €3.83 €216,187
04. Mar 19 Buy Summer Road LLC Company 22. Jan 19 24. Jan 19 19,938 €3.32 €65,745
18. Dec 18 Buy Kevin Hanley Individual 14. Dec 18 14. Dec 18 10,000 €4.87 €48,697
12. Dec 18 Buy Kevin Hanley Individual 10. Dec 18 10. Dec 18 10,000 €4.93 €49,263
10. Dec 18 Buy Daniel Bollag Individual 06. Dec 18 06. Dec 18 17,400 €5.07 €88,137
21. Aug 18 Buy Antony Mattessich Individual 20. Aug 18 20. Aug 18 20,000 €5.20 €104,054
15. Aug 18 Buy Donald Notman Individual 14. Aug 18 14. Aug 18 12,500 €5.54 €69,229
13. Aug 18 Buy Antony Mattessich Individual 10. Aug 18 10. Aug 18 16,900 €5.46 €92,221
X
Management checks
We assess Ocular Therapeutix's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Ocular Therapeutix has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant to seal corneal incisions following cataract surgery. Its lead product candidate is DEXTENZA (dexamethasone ophthalmic insert) for the treatment of post-surgical ocular pain and inflammation, allergic conjunctivitis, and dry eye diseases. The company also develops OTX-TP (intracanalicular travoprost insert) for the reduction of intraocular pressure (IOP) in patients with glaucoma and ocular hypertension; OTX-TIC, an intracameral travoprost implant for the reduction of IOP in patients with moderate to severe glaucoma and ocular hypertension; OTX-TKI, an intravitreal tyrosine kinase inhibitor implant for the treatment of wet age-related macular degeneration(AMD); and OTX-IVT, an intravitreal aflibercept implant for the treatment of wet AMD and other back-of-the-eye diseases. Its various preclinical programs include OTX-BPI for the treatment of acute ocular pain; OTX-BSI to treat post-operative Pain, and inflammation and bacterial infection; OTX-KTO for the treatment of allergy; and OTX-CSI to treat chronic dry-eye. The company has strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company’s sustained-release hydrogel in combination with Regeneron’s large molecule VEGF-targeting compounds to address conditions of the eye. Ocular Therapeutix, Inc. was founded in 2006 and is headquartered in Bedford, Massachusetts.

Details
Name: Ocular Therapeutix, Inc.
0OT
Exchange: DB
Founded: 2006
$138,648,618
42,836,572
Website: http://www.ocutx.com
Address: Ocular Therapeutix, Inc.
15 Crosby Drive,
Bedford,
Massachusetts, 01730,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM OCUL Common Stock Nasdaq Global Market US USD 25. Jul 2014
DB 0OT Common Stock Deutsche Boerse AG DE EUR 25. Jul 2014
Number of employees
Current staff
Staff numbers
167
Ocular Therapeutix employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/19 21:56
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/04
Last earnings filing: 2019/03/07
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.